Bansal N, Blanco JG, Sharma UC, Pokharel S, Shisler S, Lipshultz SE. Cardiovascular diseases in survivors of childhood cancer. Cancer Metastasis Rev. 2020;39(1):55–68. https://doi.org/10.1007/s10555-020-09859-w.
Article PubMed PubMed Central Google Scholar
Sieswerda E, van Dalen EC, Postma A, Caron HN, Kremer LCM. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Syst Rev. 2009 (4). Art. No.: CD008011. https://doi.org/10.1002/14651858.CD008011.
• Armenian SH, Hudson MM, Mulder RL, Chen MH, Constine LS, Dwyer M, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2015;16:e123–e136. These guidelines are the result of an international effort to harmonize existing cardiomyopathy surveillance guidelines for survivors of childhood cancer.
Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25:3991–4008.
CAS PubMed Article Google Scholar
Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein M, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997;15(4):1544–52.
CAS PubMed Article Google Scholar
Cardinale D, Fabiani I, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020;7:26. https://doi.org/10.3389/fcvm.2020.00026.
Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005;112:3754–62. https://doi.org/10.1161/CIRCULATIONAHA.105.576850.
Hitawala G, Jain E, Castellanos L, et al. Pediatric chemotherapy drugs associated with cardiotoxicity. Cureus. 2021;13(11): e19658. https://doi.org/10.7759/cureus.19658.
Article PubMed PubMed Central Google Scholar
• Aminkeng F, et al. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol. 2016;82:683–95. This document provides evidence-based clinical practice recommendations for genetic testing for cancer patients prior to anthracycline chemotherapy to individualize therapy and prevent cardiotoxicity.
CAS PubMed PubMed Central Article Google Scholar
• Garcia-Pavia P, et al. Genetic variants associated with cancer therapy-induced cardiomyopathy. Circulation. 2019; 140:31–41. This is the first study to examine the association between rare genetic variants in cardiomyopathy genes and the occurrence of cancer therapy-induced cardiomyopathy in adult and pediatric patients.
Girolami F, Spinelli V, Passantino S, Bennati E, Calabri GB, Olivotto I, Favilli S. Hidden familial cardiomyopathies in children: role of genetic testing. Int J Cardiol. 2021;340:55–8. https://doi.org/10.1016/j.ijcard.2021.08.014.
CAS Article PubMed Google Scholar
Marstrand P, et al. Second hits in dilated cardiomyopathy. Curr Cardiol Rep. 2020;22:8.
Chang VY, Wang JJ. Pharmacogenetics of chemotherapy-induced cardiotoxicity. Curr Oncol Rep. 2018;20:52.
PubMed PubMed Central Article Google Scholar
Wasielewski M, et al. Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy. Open Heart. 2014;1(1): 000116.
van den Berg MP, et al. Familial dilated cardiomyopathy: another risk factor for anthracycline-induced cardiotoxicity? Eur J Heart Fail. 2010;12:1297–9.
Young AC, Mercer B, Perren TJ, Dodwell D. Anthracycline-induced cardiomyopathy in siblings with early breast cancer. Ann Oncol. 2011;22(7):1692. https://doi.org/10.1093/annonc/mdr272.
CAS Article PubMed Google Scholar
Franco VI, Lipshultz SE. Cardiac complications in childhood cancer survivors treated with anthracyclines. Cardiol Young. 2015;25(Suppl. 2):107–16.
Lyon AR. et al. Diagnosis and treatment of left ventricular dysfunction and heart failure in cancer patients. e-Journal of Cardiology Practice 27/02/2019;16:40. https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-16/Diagnosis-and-treatment-of-left-ventricular-dysfunction-and-heart-failure-in-cancer-patients
Burke MA, Cook SA, Seidman JG, Seidman CE. Clinical and mechanistic insights into the genetics of cardiomyopathy. J Am Coll Cardiol. 2016;68:2871–86. https://doi.org/10.1016/j.jacc.2016.08.079.
Article PubMed PubMed Central Google Scholar
Simbre VC, Duffy SA, Dadlani GH, Miller TL, Lipshultz SE. Cardiotoxicity of cancer chemotherapy: implications for children. Paediatr Drugs. 2005;7(3):187–202. https://doi.org/10.2165/00148581-200507030-00005.
Mancilla TR, et al. Doxorubicin-induced cardiomyopathy in children. Compr Physiol. 2020;9(3):905–31. https://doi.org/10.1002/cphy.c180017.
Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008;94(4):525–33.
CAS PubMed Article Google Scholar
Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol. 1998;27(1):53–68.
CAS PubMed Article Google Scholar
Trachtenberg BH, Landy DC, Franco VI, Henkel JM, Pearson EJ, Miller TL, Lipshultz SE. Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr Cardiol. 2011;32(3):342–53.
Lipshultz SE, Scully RE, Stevenson KE, Franco VI, Neuberg DS, Colan SD, et al. Hearts too small for body size after doxorubicin for childhood leukemia: Grinch syndrome. J Clin Oncol. 2014;32:10021 (abstr.).
Armenian SH, Gelehrter SK, Chow EJ. Strategies to prevent anthracycline-related congestive heart failure in survivors of childhood cancer. Cardiol Res Pract. 2012;2012: 713294.
PubMed PubMed Central Article Google Scholar
Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231–47.
CAS PubMed Article Google Scholar
Bloom MW, Hamo CE, Cardinale D, Ky B, Nohria A, Baer L, Skopicki H, Lenihan DJ, Gheorghiade M, Lyon AR, Butler J. Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging. Circ Heart Fail. 2016;9: e002661.
PubMed PubMed Central Article Google Scholar
• Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, et al. ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;2016(37):2768–801. This paper contains the latest European Guidelines on cardio-oncology.
Cardinale D, Cipolla CM. Chemotherapy-induced cardiotoxicity: importance of early detection. Expert Rev Cardiovasc Ther. 2016;14:1297–9. https://doi.org/10.1080/14779072.2016.1239528.
CAS Article PubMed Google Scholar
Cardinale D, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981–8.
CAS PubMed Article Google Scholar
Pareek N, Cevallos J, Moliner P, Shah M, Tan LL, Chambers V, Baksi AJ, Khattar RS, Sharma R, Rosen SD, Lyon AR. Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience. Eur J Heart Fail. 2018;20:721–31.
Lipshultz SE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012;30(10):1042–9. https://doi.org/10.1200/JCO.2010.30.3404.
CAS Article PubMed PubMed Central Google Scholar
Germanakis I, Kalmanti M, Parthenakis F, Nikitovic D, Stiakaki E, Patrianakos A, et al. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Int J Cardiol. 2006;108(2):212–5. https://doi.org/10.1016/j.ijcard.2005.05.006.
Ekstein S, Nir A, Rein AJ, Perles Z, Bar-Oz B, Salpeter L, et al. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children. J Pediatr Hematol Oncol. 2007;29(7):440–4. https://doi.org/10.1097/MPH.0b013e3180640d42.
CAS Article PubMed Google Scholar
Wolf CM, Reiner B, Kuhn A, Hager A, et al. Subclinical cardiac dysfunction in childhood cancer survivors on 10-years follow up correlates with cumulative anthracycline dose and is best detected by cardiopulmonary exercise testing, circulating serum biomarker, speckle tracking echocardiography and tissue Doppler imaging. Front Pediatr. 2020;8:123. https://doi.org/10.3389/fped.2020.00123.
Lipshultz SE, Cochran TR, Franco VI, Miller TL. Treatment-related cardiotoxicity in survivors of childhood cancer. Nat Rev Clin Oncol. 2013;10:697–710. https://doi.org/10.1038/nrclinonc.2013.195.
CAS Article PubMed Google Scholar
Bagnes C, Panchuk PN, Recondo G. Antineoplastic chemotherapy induced QTc prolongation. Curr Drug Saf. 2010;5:93–6.
CAS PubMed Article Google Scholar
Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102:14–25.
CAS PubMed PubMed Central Article Google Scholar
Pratila MG, Steinherz LJ, Pratilas V. Sick sinus syndrome in a teenager treated with idarubicin. J Cardiothorac Vasc Anesth. 1993;7:125–6.
CAS PubMed Article Google Scholar
Heiderneich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42:743–9.
Mulrooney DA, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339: b4606. https://doi.org/10.1136/bmj.b4606.
Article PubMed PubMed Central Google Scholar
Shapiro CL. Cancer survivorship. N Engl J Med. 2018;379(25):2438–50.
Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med. 2001;344(26):1997–2008.
留言 (0)